ArticlePloS one2015
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 76 citations in OpenAlex.
- The Potential of Exhaled Breath Analysis for Alzheimer's Disease Monitoring (mini review).Advances in experimental medicine and biology · 2026Review
- Volatile Organic Compounds (VOCs) in Neurodegenerative Diseases (NDDs): Diagnostic Potential and Analytical Approaches.Molecules (Basel, Switzerland) · 2025Review
- Review
- Detection of Volatile Organic Compounds as an emerging strategy for Parkinson's disease diagnosis and monitoring.NPJ Parkinson's disease · 2025Article
- MORE-Q, a dataset for molecular olfactorial receptor engineering by quantum mechanics.Scientific data · 2025Article
- Innovations in Alzheimer's disease diagnostic technologies: clinical prospects of novel biomarkers, multimodal integration, and non-invasive detection.Frontiers in neurology · 2025Review
- Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach.World journal of urology · 2024Article
- A fast and non-invasive artificial intelligence olfactory-like system that aids diagnosis of Parkinson's disease.European journal of neurology · 2024Article
- Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.Biomolecules · 2023Article
- Potential for Early Noninvasive COVID-19 Detection Using Electronic-Nose Technologies and Disease-Specific VOC Metabolic Biomarkers.Sensors (Basel, Switzerland) · 2023Review
- The Versatility and Diagnostic Potential of VOC Profiling for Noninfectious Diseases.BME frontiers · 2023Article
- Fecal Volatile Organic Compounds and Microbiota Associated with the Progression of Cognitive Impairment in Alzheimer's Disease.International journal of molecular sciences · 2022Article
- Breath Analysis: A Promising Tool for Disease Diagnosis-The Role of Sensors.Sensors (Basel, Switzerland) · 2022Review
- Identification of volatile compounds from bacteria by spectrometric methods in medicine diagnostic and other areas: current state and perspectives.Applied microbiology and biotechnology · 2021Review
- Validating Differential Volatilome Profiles in Parkinson's Disease.ACS central science · 2021Article
- Article
- Proof of concept for real-time detection of SARS CoV-2 infection with an electronic nose.PloS one · 2021Article
- Machine Learning Analysis of Electronic Nose in a Transdiagnostic Community Sample With a Streamlined Data Collection Approach: No Links Between Volatile Organic Compounds and Psychiatric Symptoms.Frontiers in psychiatry · 2020Article
- Human Breathomics Database.Database : the journal of biological databases and curation · 2020Article
- Electronic Nose: Recent Developments in Gas Sensing and Molecular Mechanisms of Graphene Detection and Other Materials.Materials (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) is diagnosed based upon medical history, neuropsychiatric examination, cerebrospinal fluid analysis, extensive laboratory analyses and cerebral imaging. Diagnosis is time consuming and labour intensive. Parkinson's disease (PD) is mainly diagnosed on clinical grounds.
objectiveThe primary aim of this study was to differentiate patients suffering from AD, PD and healthy controls by investigating exhaled air with the electronic nose technique. After demonstrating a difference between the three groups the secondary aim was the identification of specific substances responsible for the difference(s) using ion mobility spectroscopy. Thirdly we analysed whether amyloid beta (Aβ) in exhaled breath was causative for the observed differences between patients suffering from AD and healthy controls.
methodsWe employed novel pulmonary diagnostic tools (electronic nose device/ion-mobility spectrometry) for the identification of patients with neurodegenerative diseases. Specifically, we analysed breath pattern differences in exhaled air of patients with AD, those with PD and healthy controls using the electronic nose device (eNose). Using ion mobility spectrometry (IMS), we identified the compounds responsible for the observed differences in breath patterns. We applied ELISA technique to measure Aβ in exhaled breath condensates.
resultsThe eNose was able to differentiate between AD, PD and HC correctly. Using IMS, we identified markers that could be used to differentiate healthy controls from patients with AD and PD with an accuracy of 94%. In addition, patients suffering from PD were identified with sensitivity and specificity of 100%. Altogether, 3 AD patients out of 53 participants were misclassified. Although we found Aβ in exhaled breath condensate from both AD and healthy controls, no significant differences between groups were detected.
conclusionThese data may open a new field in the diagnosis of neurodegenerative disease such as Alzheimer's disease and Parkinson's disease. Further research is required to evaluate the significance of these pulmonary findings with respect to the pathophysiology of neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.